PREMIER workshop on ‘What constitutes a more environmentally friendly API?’
On February 2, 2021 a consortium-wide workshop was held with…
The PREMIER project brings together a world-leading multi-disciplinary consortium composed of 25 partners from the public and private sectors working to contribute to a sustainable future by proactively managing the environmental impact of medicines.
We will design a novel information and assessment system for identifying and addressing environmental risks of medicines, especially for those with limited data availability. We will explore the options to incorporate environmental considerations earlier in the drug development process to steer the development of medicines in a greener direction. Ultimately, this project will support the establishment of a new European standard for environmental protection and reassuring patients and the society at large that medicines are increasingly safe for the environment.
LATEST NEWS
Building scientific knowledge
The evidence-based information system and tools generated by PREMIER will give regulators and the scientific community access to valuable knowledge that can be used to advance on the responsible use of medicines.
Fostering animal welfare
PREMIER will develop innovative tools and models to reduce the need for animal testing, contributing to the survival and protection of a range of species and the ecosystems at large.
Supporting the development of a new European standard for environmental protection
By facilitating access to data and tools to regulators, environmental organisations and policy makers, a new standard for environmental protection across Europe can be adopted. This will strengthen the competitiveness of the European pharmaceutical industry and will promote the industrial leadership of the European Union.
Funding period:
01/09/2020 to 30/08/2026.
72 months
EFPIA companies:
10
Academic & SMEs:
15
Total Budget:
€ 9 Million
IMI contribution:
€ 4.5 Million (in cash).
EFPIA contribution:
€ 4.5 Million (in kind)
Project Coordinator:
Radboud University Nijmegen
Project Leader:
AstraZeneca AB
